These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31641525)

  • 1. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
    Chai S; Yu S; Yang Z; Wu S; Gao L; Wang H; Zhang Y; Zhan S; Ji L; Sun F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000728. PubMed ID: 31641525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
    Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
    Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
    Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
    Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
    Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
    BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
    Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
    BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
    [No Abstract]   [Full Text] [Related]  

  • 9. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Gao L; Yu S; Cipriani A; Wu S; Huang Y; Zhang Z; Yang J; Sun Y; Yang Z; Chai S; Zhang Y; Ji L; Zhan S; Sun F
    Aging Dis; 2019 Dec; 10(6):1311-1319. PubMed ID: 31788342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
    Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
    J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.
    Xu L; Yu SQ; Gao L; Huang Y; Wu SS; Yang J; Sun YX; Yang ZR; Chai SB; Zhang Y; Ji LN; Sun F; Zhan SY
    Biomed Environ Sci; 2020 Jan; 33(1):37-47. PubMed ID: 32029057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.
    Wang W; Gao Y; Chen D; Wang C; Feng X; Ran X
    Diabetes Res Clin Pract; 2017 Jul; 129():213-223. PubMed ID: 28552612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.
    Wang T; Wang F; Zhou J; Tang H; Giovenale S
    Diabetes Metab Res Rev; 2016 Nov; 32(8):843-857. PubMed ID: 27037787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.